ValuEngine cut shares of Eli Lilly And Co (NYSE:LLY) from a buy rating to a hold rating in a report issued on Tuesday morning.
Several other research firms have also commented on LLY. Morgan Stanley raised their price target on Eli Lilly And Co from $93.00 to $102.00 and gave the stock an equal weight rating in a research report on Tuesday, July 31st. TheStreet lowered Eli Lilly And Co from a b rating to a c+ rating in a research report on Friday, August 24th. Guggenheim started coverage on Eli Lilly And Co in a research report on Monday, October 8th. They set a buy rating for the company. Cantor Fitzgerald restated a buy rating and set a $128.00 price target on shares of Eli Lilly And Co in a research report on Wednesday, October 17th. Finally, Barclays restated an overweight rating and set a $112.00 price target (up from $107.00) on shares of Eli Lilly And Co in a research report on Tuesday, September 18th. Eight research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $111.53.
LLY opened at $105.90 on Tuesday. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $116.61. The firm has a market cap of $114.65 billion, a PE ratio of 21.22, a PEG ratio of 1.73 and a beta of 0.29. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be issued a $0.5625 dividend. The ex-dividend date is Wednesday, November 14th. This represents a $2.25 dividend on an annualized basis and a yield of 2.12%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 52.57%.
In related news, major shareholder Lilly Endowment Inc sold 14,632 shares of Eli Lilly And Co stock in a transaction on Monday, October 8th. The stock was sold at an average price of $115.91, for a total value of $1,695,995.12. Following the completion of the transaction, the insider now directly owns 119,191,172 shares in the company, valued at $13,815,448,746.52. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Alfonso G. Zulueta sold 7,000 shares of Eli Lilly And Co stock in a transaction on Thursday, October 4th. The shares were sold at an average price of $114.64, for a total value of $802,480.00. Following the completion of the transaction, the senior vice president now owns 45,224 shares of the company’s stock, valued at $5,184,479.36. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,185,271 shares of company stock valued at $123,843,752. 0.11% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Comgest Global Investors S.A.S. raised its stake in Eli Lilly And Co by 17.2% in the third quarter. Comgest Global Investors S.A.S. now owns 1,547,900 shares of the company’s stock valued at $166,105,000 after buying an additional 227,200 shares in the last quarter. Advisor Partners LLC raised its stake in Eli Lilly And Co by 3.6% in the third quarter. Advisor Partners LLC now owns 26,003 shares of the company’s stock valued at $2,790,000 after buying an additional 893 shares in the last quarter. Parametrica Management Ltd acquired a new stake in Eli Lilly And Co in the third quarter valued at $265,000. Systematic Financial Management LP acquired a new stake in Eli Lilly And Co in the third quarter valued at $2,123,000. Finally, Asset Planning Services Inc. LA ADV acquired a new stake in Eli Lilly And Co in the third quarter valued at $249,000. Hedge funds and other institutional investors own 76.17% of the company’s stock.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: Trading Penny Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.